ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0184

Exploring Patient Journeys and Education Needs of Hispanic Individuals with Rheumatoid Arthritis
Abstract Number: 0185

Empowered2work: Development and Delivery of a Multi-faceted Peer-coaching Workshop Focusing on Health Promotion and Ergonomic Issues in the Workplace
Abstract Number: 0186

Evaluating the Effectiveness & Impact of an In-Person Peer Support Group That Transitioned to a Virtual Platform During the COVID-19 Pandemic
Abstract Number: 0187

Patient-reported Outcomes and Quality of Life in Patients with Rheumatoid Arthritis Treated with GP2015: Final Results from a Real-world Study
Abstract Number: 0188

COVID-19 and Autoimmune Rheumatic Patients: Behavioral Changes Adopted by Patients in the Midst of the Pandemic
Abstract Number: 0189

Characteristics Associated with a Positive PEST Screening Among Patients with Psoriasis Without a Diagnosis of Psoriatic Arthritis: Results from the Global Psoriasis and Beyond Study
Abstract Number: 0190

Effect of Shared Decision-making on Trust in Physician in the Clinical Practice of Systemic Lupus Erythematosus: The TRUMP2-SLE Study
Abstract Number: 0191

Patient-reported Outcomes to Assess Dyspnea in Connective Tissue Diseases, Interstitial Lung Disease and Pulmonary Hypertension, a Systematic Literature Review of Measurement Properties
Abstract Number: 0192

Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis
Abstract Number: 0193

Factors Influencing Visit Preference in Patients with Rheumatic Diseases: A Qualitative Study
Abstract Number: 0194

A Survey of Patients with Ehlers Danlos Syndrome and Their Interest in Multidisciplinary Care
Abstract Number: 0195

Acceptance of Virtual Reality for Managing Their Disease Among People with Rheumatologic Conditions with and Without Prior Experience Using Virtual Reality
Abstract Number: 0196

The Impact of Barometric Pressure Waves on Connective Tissue Disorders
Abstract Number: 0197

Is Similar the Same? How We Incorporated Feedback from 250 Patients into a CME Activity on Biosimilars
Abstract Number: 0198

Patient Perspectives on Janus Kinase Inhibitor Use in the Treatment of Inflammatory Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].